Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01970969 · ClinicalTrials.gov registry record

THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring

A clinical trial, sponsored by Scripps Translational Science Institute.

Completed
Registry status
928
Enrollment target

NCT01970969 is a clinical trial that has completed, run by Scripps Translational Science Institute. The registered enrollment target is 928 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01970969 has completed, sponsored by Scripps Translational Science Institute.

COMPLETED
Registry status
928 participants
Enrollment target

Study Summary

Our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide polymorphisms (SNPs) that are associated with atrial fibrillation at the Genome Wide Association Study (GWAS) level is associated with the development of atrial fibrillation among previously undiagnosed patients at high risk for atrial fibrillation. A current example of these SNPs is shown in Table 1. As a secondary hypothesis, we will test the association between atrial fibrillation diagnosed in this study with a subset of SNPs reported to be associated with atrial fibrillation and with fine-mapping SNPs. We will also test the association between atrial fibrillation of less than and greater than 30 seconds and a panel of approximately 10 SNPs.

Trial Details

FieldValue
Enrollment Target 928 participants
Start Date 2013-09
Est. Completion 2017-12

What the Registry Record Tells You About NCT01970969

The ClinicalTrials.gov registry entry for NCT01970969 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 928 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01970969 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01970969 about?

NCT01970969 is a clinical study titled "THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring". Our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide polymorphisms (SNPs) that are associated with atrial fibrillation at the Genome Wide Association Study (GWAS) level is associated with the development of atrial fibrillation among previously undiagnosed patie...

What is the current status of trial NCT01970969?

This trial is currently completed. The enrollment target is 928 participants. The study started on 2013-09. Estimated completion is 2017-12.

Who is sponsoring clinical trial NCT01970969?

This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.